Cargando…

Structural determinants of TRPV4 inhibition and identification of new antagonists with antiviral activity

BACKGROUND AND PURPOSE: The transient receptor potential vanilloid 4 (TRPV4) cation channel participates in multiple physiological processes and is also at the core of different diseases, making this channel an interesting pharmacological target with therapeutic potential. However, little is known a...

Descripción completa

Detalles Bibliográficos
Autores principales: Doñate‐Macian, Pablo, Duarte, Yorley, Rubio‐Moscardo, Fanny, Pérez‐Vilaró, Gemma, Canan, Jonathan, Díez, Juana, González‐Nilo, Fernando, Valverde, Miguel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291951/
https://www.ncbi.nlm.nih.gov/pubmed/32959389
http://dx.doi.org/10.1111/bph.15267
_version_ 1784749253260738560
author Doñate‐Macian, Pablo
Duarte, Yorley
Rubio‐Moscardo, Fanny
Pérez‐Vilaró, Gemma
Canan, Jonathan
Díez, Juana
González‐Nilo, Fernando
Valverde, Miguel A.
author_facet Doñate‐Macian, Pablo
Duarte, Yorley
Rubio‐Moscardo, Fanny
Pérez‐Vilaró, Gemma
Canan, Jonathan
Díez, Juana
González‐Nilo, Fernando
Valverde, Miguel A.
author_sort Doñate‐Macian, Pablo
collection PubMed
description BACKGROUND AND PURPOSE: The transient receptor potential vanilloid 4 (TRPV4) cation channel participates in multiple physiological processes and is also at the core of different diseases, making this channel an interesting pharmacological target with therapeutic potential. However, little is known about the structural elements governing its inhibition. EXPERIMENTAL APPROACH: We have now combined in silico drug discovery and molecular dynamics simulation based on Xenopus tropicalis xTRPV4 structure with functional studies measuring cell Ca(2+) influx mediated by human TRPV4 channel to characterize the binding site of known TRPV4 inhibitors and to identify novel small molecule channel modulators. KEY RESULTS: We have found that the inhibitor HC067047 binds to a pocket conformed by residues from S2–S3 linker (xTRPV4‐D542), S4 (xTRPV4‐M583 and Y587 and S5 (xTRPV4‐D609 and F613). This pocket was also used for structure‐based virtual screening in the search of novel channel modulators. Forty potential hits were selected based on the lower docking scores (from ~250,000 compounds) and their effect upon TRPV4 functionally tested. Three were further analysed for stability using molecular dynamics simulation and functionally tested on TRPV4 channels carrying mutations in the binding pocket. Compound NSC151066, shown to require residue xTRPV4‐M583 for its inhibitory effect, presented an IC(50) of 145 nM and demonstrated to be an effective antiviral against Zika virus with a potency similar to HC067047. CONCLUSION AND IMPLICATIONS: Together, we propose structural insights into the inhibition of TRPV4 and how this information can be used for the design of novel channel modulators. LINKED ARTICLES: This article is part of a themed issue on Structure Guided Pharmacology of Membrane Proteins (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.14/issuetoc
format Online
Article
Text
id pubmed-9291951
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92919512022-07-20 Structural determinants of TRPV4 inhibition and identification of new antagonists with antiviral activity Doñate‐Macian, Pablo Duarte, Yorley Rubio‐Moscardo, Fanny Pérez‐Vilaró, Gemma Canan, Jonathan Díez, Juana González‐Nilo, Fernando Valverde, Miguel A. Br J Pharmacol Article BACKGROUND AND PURPOSE: The transient receptor potential vanilloid 4 (TRPV4) cation channel participates in multiple physiological processes and is also at the core of different diseases, making this channel an interesting pharmacological target with therapeutic potential. However, little is known about the structural elements governing its inhibition. EXPERIMENTAL APPROACH: We have now combined in silico drug discovery and molecular dynamics simulation based on Xenopus tropicalis xTRPV4 structure with functional studies measuring cell Ca(2+) influx mediated by human TRPV4 channel to characterize the binding site of known TRPV4 inhibitors and to identify novel small molecule channel modulators. KEY RESULTS: We have found that the inhibitor HC067047 binds to a pocket conformed by residues from S2–S3 linker (xTRPV4‐D542), S4 (xTRPV4‐M583 and Y587 and S5 (xTRPV4‐D609 and F613). This pocket was also used for structure‐based virtual screening in the search of novel channel modulators. Forty potential hits were selected based on the lower docking scores (from ~250,000 compounds) and their effect upon TRPV4 functionally tested. Three were further analysed for stability using molecular dynamics simulation and functionally tested on TRPV4 channels carrying mutations in the binding pocket. Compound NSC151066, shown to require residue xTRPV4‐M583 for its inhibitory effect, presented an IC(50) of 145 nM and demonstrated to be an effective antiviral against Zika virus with a potency similar to HC067047. CONCLUSION AND IMPLICATIONS: Together, we propose structural insights into the inhibition of TRPV4 and how this information can be used for the design of novel channel modulators. LINKED ARTICLES: This article is part of a themed issue on Structure Guided Pharmacology of Membrane Proteins (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.14/issuetoc John Wiley and Sons Inc. 2020-10-15 2022-07 /pmc/articles/PMC9291951/ /pubmed/32959389 http://dx.doi.org/10.1111/bph.15267 Text en © 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Article
Doñate‐Macian, Pablo
Duarte, Yorley
Rubio‐Moscardo, Fanny
Pérez‐Vilaró, Gemma
Canan, Jonathan
Díez, Juana
González‐Nilo, Fernando
Valverde, Miguel A.
Structural determinants of TRPV4 inhibition and identification of new antagonists with antiviral activity
title Structural determinants of TRPV4 inhibition and identification of new antagonists with antiviral activity
title_full Structural determinants of TRPV4 inhibition and identification of new antagonists with antiviral activity
title_fullStr Structural determinants of TRPV4 inhibition and identification of new antagonists with antiviral activity
title_full_unstemmed Structural determinants of TRPV4 inhibition and identification of new antagonists with antiviral activity
title_short Structural determinants of TRPV4 inhibition and identification of new antagonists with antiviral activity
title_sort structural determinants of trpv4 inhibition and identification of new antagonists with antiviral activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291951/
https://www.ncbi.nlm.nih.gov/pubmed/32959389
http://dx.doi.org/10.1111/bph.15267
work_keys_str_mv AT donatemacianpablo structuraldeterminantsoftrpv4inhibitionandidentificationofnewantagonistswithantiviralactivity
AT duarteyorley structuraldeterminantsoftrpv4inhibitionandidentificationofnewantagonistswithantiviralactivity
AT rubiomoscardofanny structuraldeterminantsoftrpv4inhibitionandidentificationofnewantagonistswithantiviralactivity
AT perezvilarogemma structuraldeterminantsoftrpv4inhibitionandidentificationofnewantagonistswithantiviralactivity
AT cananjonathan structuraldeterminantsoftrpv4inhibitionandidentificationofnewantagonistswithantiviralactivity
AT diezjuana structuraldeterminantsoftrpv4inhibitionandidentificationofnewantagonistswithantiviralactivity
AT gonzaleznilofernando structuraldeterminantsoftrpv4inhibitionandidentificationofnewantagonistswithantiviralactivity
AT valverdemiguela structuraldeterminantsoftrpv4inhibitionandidentificationofnewantagonistswithantiviralactivity